Yes - a very positive quarterly. A great cash position to be in, and things are looking good for PTX-100 and PTX-200.
Omnicar is hugely interesting to me, and I would like to know more about the Cell Therapies collaboration with the Peter MacCallum Cancer Centre. My assumption is that the cell therapies research may be aimed at improving Omnicar, but only time will tell.
The acquisition of Dr Lim as Director of Scientific Affairs is also a big plus for Prescient. Her background and experience look like a great fit, and this will really strengthen their scientific capability.
Prescient has an extremely impressive set of IP and projects for a company with a market cap of just $61m.
Cheers
Dave
PTX Price at posting:
9.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)